Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLES - Schedule of intangible assets (Details)

v3.21.2
INTANGIBLES - Schedule of intangible assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Intangibles          
Total intangible assets $ 19,003   $ 19,003   $ 19,006
Accumulated amortization (5,960)   (5,960)   (3,977)
Net intangible assets 13,043   13,043   15,029
Amortization expense 700 $ 400 $ 1,983 $ 1,065  
Ceracade          
Intangibles          
Estimated Useful Lives (Years)     3 years    
Total intangible assets 300   $ 300   300
Luxamend          
Intangibles          
Estimated Useful Lives (Years)     3 years    
Total intangible assets 50   $ 50   50
Targadox          
Intangibles          
Estimated Useful Lives (Years)     3 years    
Total intangible assets 1,250   $ 1,250   1,250
Ximino          
Intangibles          
Estimated Useful Lives (Years)     7 years    
Total intangible assets 7,134   $ 7,134   7,134
Net intangible assets 4,926   $ 4,926    
Exelderm          
Intangibles          
Estimated Useful Lives (Years)     3 years    
Total intangible assets 1,600   $ 1,600   1,600
Accutane          
Intangibles          
Estimated Useful Lives (Years)     5 years    
Total intangible assets 4,727   $ 4,727   4,727
Net intangible assets 4,175   $ 4,175    
Anti-itch product          
Intangibles          
Estimated Useful Lives (Years)     3 years    
Total intangible assets 3,942   $ 3,942   $ 3,945
Amortization expense $ 0   $ 0